SCHEMBL11922782

SCHEMBL11922782

CCCCNCc1ccc(N(CC)CC)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ CA12 O43570 4/20 0.42
▸ CA2 P00918 4/20 0.42
▸ CA9 Q16790 4/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ GFER P55789 1/20 0.42
▸ MPO P05164 3/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ CRHBP P24387 1/20 0.40
▸ CRHR2 Q13324 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ SLC6A4 P31645 2/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20313355 0.78 CA12 (0.47) CA12CA2CA9KDM4ETSHR
SCHEMBL2472187 0.76 ALDH1A1 (0.50) LMNAKDM4EMEN1KMT2AALDH1A1
SCHEMBL1600055 0.76 ALDH1A1 (0.50) LMNAKDM4EHSD17B10MEN1KMT2A
SCHEMBL11529878 0.74 LMNA (0.60) LMNAMEN1KMT2AGFERALDH1A1
SCHEMBL8347522 0.74 NAAA (0.46) LMNACA12CA2KDM4ETSHR
SCHEMBL4632526 0.74 ALDH1A1 (0.48) LMNAKDM4EMEN1KMT2AALDH1A1
SCHEMBL20313356 0.73 CA12 (0.51) LMNACA12CA2CA9KDM4E
SCHEMBL20535946 0.73 CA12 (0.79) CA12CA2CA9KDM4ETSHR
SCHEMBL8357877 0.72 MAPT (0.58) LMNAKDM4EMEN1KMT2AALDH1A1
SCHEMBL1600420 0.71 ALDH1A1 (0.46) LMNAKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236965-B2 Benzimidazole derivatives and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-08-07 — — US disclosed
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2009-07-02 — — US disclosed
US-7495110-B2 Benzimidazole derivatives and their use as GnRH antagonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament GNRHR, FSHR, KISS1R LMNA 3127/4885CA12 2823/4885CA2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback